Orrick's Joshua Rosenkranz helped Gilead Sciences successfully defend a Federal Circuit judgment of patent invalidity. (Courtesy photo) Mission Impossible? All-Star Lawyers Couldn't Convince Supreme Court in High-Stakes Case
Bristol-Myers Squibb had won a $1.2 billion judgment for infringement of its patent on a cancer treatment. But the justices left in place a Federal Circuit decision that invalidated the patent for failing to meet the Patent Act's written description requirement.
November 08, 2022 at 02:54 PM
3 minute read
Intellectual Property
An all-star team of patent litigators could not persuade the U.S. Supreme Court to revive a $1.2 billion judgment over a cancer treatment patent.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3'That's Disappointing': Only 11% of MDL Appointments Went to Attorneys of Color in 2023
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
